Thermo Fisher Scientific Earns Top Score for LGBTQ+ Workplace Equality for Seventh Consecutive Year

Thermo Fisher Scientific Earns Top Score for LGBTQ+ Workplace Equality for Seventh Consecutive Year WALTHAM, Mass., Jan. 27, 2022 /PRNewswire/ — Thermo Fisher Scientific Inc., (NYSE:TMO), the world leader in serving science, received a score of 100 on the Human Rights Campaign Foundation’s 2022 Corporate Equality Index (CEI) for the seventh consecutive year. As the... Read more

Danaher Reports Fourth Quarter And Full Year 2021 Results

WASHINGTON, Jan. 27, 2022 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (the “Company”) today announced results for the fourth quarter and full year 2021. All results in this release reflect only continuing operations unless otherwise noted. For the quarter ended December 31, 2021, net earnings were $1.8 billion, or $2.39 per diluted common share which represents a... Read more

Advancing Imaging Frontiers with the new Oxford-ZEISS Centre of Excellence

In December 2021, ZEISS entered a strategic partnership with the Kennedy Institute of Rheumatology (KIR) and the Institute of Developmental and Regenerative Medicine (IDRM), developing the Oxford-ZEISS Centre of Excellence (Oxford-ZCoE). The Kennedy Institute of Rheumatology (KIR) is a world-leading medical research centre where discovery research drives development of transformative therapies for chronic inflammatory and... Read more

Thermo Fisher Scientific Earns NSF/ANSI 456 Vaccine Storage Certification for its High-Performance Refrigerators and Freezers

Thermo Fisher Scientific Earns NSF/ANSI 456 Vaccine Storage Certification for its High-Performance Refrigerators and Freezers Thermo Scientific TSX and TSG Series meet stringent requirements for ensuring the safe storage and efficacy of temperature-sensitive vaccines, including those for COVID-19 CARLSBAD, Calif., Jan. 25, 2022 /PRNewswire/ — High-performance pharmacy refrigerators and freezers from Thermo Fisher Scientific, already certified... Read more

Roche’s Evrysdi (risdiplam) granted FDA priority review for treatment of pre-symptomatic babies under 2 months of age with spinal muscular atrophy (SMA)

Interim data submitted to the FDA show majority of pre-symptomatic babies treated with Evrysdi for at least one year were able to sit, stand and walk within timeframes typical of healthy babies, as well as maintain swallowing Evrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated... Read more